Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Julius

Showing results (61-70 of 115) with videos related to

Pageof 12
Sort By:
Atherosclerosis. Supplements|January 30, 2013
Current situation of lipoprotein apheresis in SaxonyU Julius, K Taseva, S Fischer, et al.
Clinical Research in Cardiology Supplements|March 7, 2019
Lipoprotein(a)-an interdisciplinary challengeU Julius, S Tselmin, U Schatz, et al.
Deutsche Medizinische Wochenschrift (1946)|May 29, 2014
[Lipoprotein(a): a risk factor for atherosclerosis]S Fischer, U Julius, S Tselmin, et al.
Clinical Research in Cardiology Supplements|March 7, 2019
Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitorsU Julius, S Tselmin, U Schatz, et al.
European Journal of Epidemiology|August 2, 2003
Lipid-lowering therapy and cholesterol levels following acute myocardial infarction: a German study of 5361 patientsA Bergmann, J Schulze, D Hübner, et al.
Atherosclerosis. Supplements|May 5, 2015
Mental symptoms and quality of life in lipoprotein apheresis patients in comparison to hemodialysis patients, platelet donors and normal populationE Stasiewski, M Christoph, A Christoph, et al.
Acta Diabetologica Latina|July 1, 1981
Hyperinsulinemia in patients with low fractional catabolic rate of triglyceridesU Julius, W Leonhardt, J Schulze, et al.
Annals of Clinical Research|January 1, 1988
More exercise for the hyperlipidaemic patients?M Hanefeld, S Fischer, U Julius, et al.
Fortschritte Der Medizin|December 20, 1992
[Different effects of fibrates on the lipoprotein profile. Comparison of the effectiveness of gemfibrozil and bezafibrate in various types of hyperlipoproteinemia]U Julius, C Hora, P Gross, et al.
Monographs on Atherosclerosis|January 1, 1985
The Diabetes Intervention Study (DIS): a cooperative multi-intervention trial with newly manifested type II diabetics: preliminary resultsM Hanefeld, J Schulze, S Fischer, et al.
Pageof 12

Showing results (61-70 of 115) with videos related to

Sort By:
Pageof 12
Atherosclerosis. Supplements|January 30, 2013
Current situation of lipoprotein apheresis in SaxonyU Julius, K Taseva, S Fischer, et al.
Clinical Research in Cardiology Supplements|March 7, 2019
Lipoprotein(a)-an interdisciplinary challengeU Julius, S Tselmin, U Schatz, et al.
Deutsche Medizinische Wochenschrift (1946)|May 29, 2014
[Lipoprotein(a): a risk factor for atherosclerosis]S Fischer, U Julius, S Tselmin, et al.
Clinical Research in Cardiology Supplements|March 7, 2019
Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitorsU Julius, S Tselmin, U Schatz, et al.
European Journal of Epidemiology|August 2, 2003
Lipid-lowering therapy and cholesterol levels following acute myocardial infarction: a German study of 5361 patientsA Bergmann, J Schulze, D Hübner, et al.
Atherosclerosis. Supplements|May 5, 2015
Mental symptoms and quality of life in lipoprotein apheresis patients in comparison to hemodialysis patients, platelet donors and normal populationE Stasiewski, M Christoph, A Christoph, et al.
Acta Diabetologica Latina|July 1, 1981
Hyperinsulinemia in patients with low fractional catabolic rate of triglyceridesU Julius, W Leonhardt, J Schulze, et al.
Annals of Clinical Research|January 1, 1988
More exercise for the hyperlipidaemic patients?M Hanefeld, S Fischer, U Julius, et al.
Fortschritte Der Medizin|December 20, 1992
[Different effects of fibrates on the lipoprotein profile. Comparison of the effectiveness of gemfibrozil and bezafibrate in various types of hyperlipoproteinemia]U Julius, C Hora, P Gross, et al.
Monographs on Atherosclerosis|January 1, 1985
The Diabetes Intervention Study (DIS): a cooperative multi-intervention trial with newly manifested type II diabetics: preliminary resultsM Hanefeld, J Schulze, S Fischer, et al.
Pageof 12